Clinical Trial Search

Phase 4 N=54 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Candidemia · Invasive Candidiasis

Primary: Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment — 26; 18 participants

Pfizer Results Jan 2011 53.7% serious AE View details

Phase 4 N=1,060 A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

Cardiovascular Disease

Primary: The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration — 0 Participants

Lantheus Medical Imaging Results Jan 2011 0.0% serious AE View details

Phase 4 N=26 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

Primary: Initial Recovery — 1.7; 1.6; 1.8 IU/dL per IU/kg — p=0.1662

Baxalta now part of Shire Results Jan 2011 0.0% serious AE View details

Phase 4 N=40 Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis A · Hepatitis B

Primary: Number of Subjects Seropositive for Anti-hepatitis A Virus Antibodies (Anti-HAV) and Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies and With Anti-HBs Antibody…

GlaxoSmithKline Results Jan 2011 0.0% serious AE View details

Phase 4 N=332 Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

Hypertension

Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment — 168.2; 168.1; 138.8; 139.1 mm Hg

Novartis Pharmaceuticals Results Jan 2011 2.4% serious AE View details

Phase 4 N=532 Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

Hypertension

Primary: Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP) — -30.38; -20.15 mm Hg

Novartis Results Jan 2011 1.3% serious AE View details

Phase 4 N=313 Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients

Kidney Transplantation

Primary: Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death — 33; 36…

Novartis Results Jan 2011 46.7% serious AE View details

Phase 4 N=256 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Essential Hypertension ( Mild to Moderate)

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Novartis Results Jan 2011 0.5% serious AE View details

Phase 4 N=34 A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients

Liver Transplantation

Primary: Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation — 8; 26 Participants

Novartis Pharmaceuticals Results Jan 2011 50.8% serious AE View details

Phase 4 N=546 Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Hypertension

Primary: Absolute Reduction From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) on Ambulatory Blood Pressure Monitoring — -12.01; -11.3 mmHg

Novartis Pharmaceuticals Results Jan 2011 0.7% serious AE View details

Phase 4 N=75 Clinical Evaluation of a New Aspheric Intraocular Lens.

Cataract

Primary: Low Contrast Best Corrected Visual Acuity Following Cataract Surgery — 0.22; 0.24 LogMAR

Bausch & Lomb Incorporated Results Jan 2011 0.0% serious AE View details

Phase 4 N=60 A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

GlaxoSmithKline Results Jan 2011 0.0% serious AE View details

Phase 4 N=13 Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Alpha 1-Antitrypsin Deficiency

Primary: Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level — 0.28 μM — p=0.0195

Baxalta now part of Shire Results Jan 2011 7.7% serious AE View details

Phase 4 N=60 FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

HIV Infections

Primary: Percentage of Participants Who Maintained Virologic Suppression (Less Than 50 RNA Cps/ml) — 100; 86 Percentage of Participants

Community Research Initiative of New England Results Jan 2011 3.3% serious AE View details

Phase 4 N=249 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Primary: Mean Change From Baseline in Aortic Pulse Wave Velocity (aPWV) at the 12-Week Endpoint — 10.06; 9.87; 9.83; 9.95 meters per second (m/s) — p=0.065

GlaxoSmithKline Results Dec 2010 6.4% serious AE View details